[1]苟于芬 王宏宇,7,8.动脉粥样硬化的免疫机制与治疗的研究进展[J].心血管病学进展,2024,(10):912.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.010]
　GOU Yufen,ZHANG Hong,WANG Hongyu,et al.Advances in Immune Mechanisms and Treatment of Atherosclerosis[J].Advances in Cardiovascular Diseases,2024,(10):912.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.010]
点击复制

动脉粥样硬化的免疫机制与治疗的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2024年10期
页码:
912
栏目:
综述
出版日期:
2024-10-25

文章信息/Info

Title:
Advances in Immune Mechanisms and Treatment of Atherosclerosis
作者:
苟于芬1 王宏宇1; 2; 3; 4; 5; 6; 7; 8
（1.新疆医科大学第二临床医学院,新疆 乌鲁木齐 830054；2.北京大学首钢医院血管医学中心，北京 100144；3.北京市石景山区血管医学重点学科，北京 100144；4.北京大学医学部血管健康研究中心，北京 100144；5.血管稳态和重构全国重点实验室（北京大学），北京 100191；6.北京大学临床研究所心脏和血管健康研究中心，北京 100191；7.成都医学院心脏和血管健康研究中心,四川 成都 611730；8.北京大学健康医疗大数据国家研究院智慧化心脏和血管健康数字管理研究中心，北京 100191）
Author(s):
GOU Yufen 1; ZHANG Hong 2; WANG Hongyu 1; 2; 3; 4; 5; 6; 7; 8
(1.The Second Affiliated Hospital of Xinjiang Medical University,Urumqi 830054,Xinjiang,China;2.Peking University Shougang Hospital Vascular Medicine Center,Beijing 100144,China;3.Beijing Shijingshan District Vascular Medicine Key Specialty,Beijing 100144,China;4.Vascular Health Research Center of Peking University Health Science Center(VHRC-PKUHSC),Beijing 100144,China5.National Key Laboratory of Vascular Homeostasis and Remodeling(Peking University),Beijing 100191,China;6.Heart and Vascular Health Research Center of Peking University Clinical Research Institute(HVHRC-PUCRI),Beijing 100191,China;7.Heart and Vascular Health Research Center of Chengdu Medical College,Sichuan(HVHRC-CMC),Chengdu 611730,Sichuan,China;8.Intelligent Heart and Vascular Health Digital Management Research Center,National Institute of Health Data Science At Peking University,Beijing 100191,China) )
关键词:
动脉粥样硬化; 免疫机制; 免疫细胞; 免疫治疗
Keywords:
Atherosclerosis; Immune mechanism; Immunocyte; Immunotherapy
DOI:
10.16806/j.cnki.issn.1004-3934.2024.10.010
摘要:
动脉粥样硬化（AS）是心血管疾病的首要原因，脑梗死、心肌梗死等等并发症致残率及致死率高，严重影响人们的生活质量。在AS进程中，炎症是该病发生发展的核心。炎症激活巨噬细胞、中性粒细胞、T淋巴细胞等免疫细胞，并释放γ干扰素、肿瘤坏死因子-α和白细胞介素等炎症因子。这些炎症因子加剧活性氧的生成，活性氧导致斑块内氧化应激和组织损伤，进而破坏血管内皮的完整性及促进泡沫细胞形成、平滑肌细胞增殖和脂质沉积，最终形成斑块。同时，炎症还影响斑块的稳定性，增加斑块破裂的风险。因此，免疫炎症和AS之间存在密切联系，免疫细胞的异常激活和炎症因子的释放使斑块形成进而导致心血管疾病的发生。现对AS的免疫机制及治疗方法做一综述。
Abstract:
Atherosclerosis (AS) is the primary cause of cardiovascular diseases,and the mortality and disability rate of cerebral infarction,myocardial infarction and other complications are high,which seriously affects people’s quality of life. In the course of AS,inflammation is the core of the development of the disease. Inflammation activates immune cells such as macrophages,neutrophils,and T lymphocytes,and releases inflammatory factors such as gamma-interferon,tumor necrosis factor-α,and interleukin. These inflammatory factors exacerbate the production of reactive oxygen species,which lead to oxidative stress and tissue damage in plaques,thereby destroying the integrity of vascular endothelia and promoting foam cell formation,smooth muscle cell proliferation and lipid deposition,and eventually plaque formation. At the same time,inflammation also affects plaque stability and increases the risk of plaque rupture. Therefore,there is a close relationship between immune inflammation and AS,and the abnormal activation of immune cells and the release of inflammatory factors lead to the formation of plaque,which leads to the occurrence of cardiovascular diseases. This article reviews the immune mechanism and treatment of AS

参考文献/References:

[1].《中国心血管健康与疾病报告2022》编写组. 《中国心血管健康与疾病报告2022》要点解读[J]. 中国心血管杂志,2023,28(4):297-312.
[2].陈捷,王宏宇. 淋巴系统与心血管疾病的相关性研究[J]. 心血管病学进展,2021,42(7):586-589.
[3].Xu Y,Xu Y,Zhu Y,et al. Macrophage miR-34a is a key regulator of cholesterol efflux and atherosclerosis [J]. Mol Ther,2020,28(1):202-216.
[4].Mushenkova NV,Nikiforov NG,Melnichenko AA,et al. Functional phenotypes of intraplaque macrophages and their distinct roles in atherosclerosis development and atheroinflammation[J]. Biomedicines,2022,10(2):452.
[5].Chen J,Xiang X,Nie L,et al. The emerging role of Th1 cells in atherosclerosis and its implications for therapy[J]. Front Immunol,2023,13:1079668.
[6].Klopf J,Brostjan C,Eilenberg W,et al. Neutrophil extracellular traps and their implications in cardiovascular and inflammatory disease[J]. Int J Mol Sci,2021,22(2):559.
[7].Bonaventura A,Liberale L,Carbone F,et al. The pathophysiological role of neutrophil extracellular traps in inflammatory diseases[J]. Thromb Haemost,2018,118(1):6-27.
[8].王子欢,石先贵,吕建军等. 树突状细胞与动脉粥样硬化研究进展[J]. 空军军医大学学报,2023,44(8):765-769.
[9].Henein MY,Vancheri S,Longo G,et al. The role of inflammation in cardiovascular disease[J]. Int J Mol Sci,2022,23(21):12906.
[10].Marchio P,Guerra-Ojeda S,Vila JM,et al. Targeting early atherosclerosis:a focus on oxidative stress and inflammation[J]. Oxid Med Cell Longev,2019,2019:8563845.
[11].Swastini DA,Wiryanthini IAD,Ariastuti NLP,et al. Atherosclerosis prediction with high sensitivity C-reactive protein (hs-CRP) and related risk factor in patient with dyslipidemia[J]. Open Access Maced J Med Sci,2019,7(22):3887-3890.
[12].Jia X,Buckley L,Sun C,et al. Association of interleukin-6 and interleukin-18 with cardiovascular disease in older adults:atherosclerosis risk in communities study[J]. Eur J Prev Cardiol,2023,30(16):1731-1740.
[13].Pan J,Hu J,Qi X,et al. Association study of a functional variant of TNF-α gene and serum TNF-α level with the susceptibility of congenital heart disease in a Chinese population[J]. Postgrad Med J,2019,95(1128):547-551.
[14].Pu Y,Li S,Wang L,et al. Association between high-sensitivity C-reactive protein and prognosis of patients with acute cerebral infarction[J]. Neuropsychiatr Dis Treat,2022,18:1771-1778.
[15].Custodero C,Ciavarella A,Panza F,et al. Role of inflammatory markers in the diagnosis of vascular contributions to cognitive impairment and dementia:a systematic review and meta-analysis[J]. Geroscience,2022,44(3):1373-1392.
[16].Ridker PM,MacFadyen JG,Everett BM,et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab:a secondary analysis from the CANTOS randomised controlled trial[J]. Lancet,2018,391(10118):319-328.
[17].Ridker PM,Libby P,MacFadyen JG,et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality:analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)[J]. Eur Heart J,2018,39(38):3499-3507.
[18].Everett BM,MacFadyen JG,Thuren T,et al. Inhibition of interleukin-1β and reduction in atherothrombotic cardiovascular events in the CANTOS trial[J]. J Am Coll Cardiol,2020,76(14):1660-1670.
[19].Ridker PM,Everett BM,Thuren T,et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease[J]. N Engl J Med,2017,377(12):1119-1131.
[20].Deftereos SG,Beerkens FJ,Shah B,et al. Colchicine in cardiovascular disease:in-depth review[J]. Circulation,2022,145(1):61-78.
[21].Soehnlein O,Libby P. Targeting inflammation in atherosclerosis—From experimental insights to the clinic[J]. Nat Rev Drug Discov,2021,20(8):589-610.
[22].Tardif JC,Kouz S,Waters DD,et al. Efficacy and safety of low-dose colchicine after myocardial infarction[J]. N Engl J Med,2019,381(26):2497-2505.
[23].Visseren FLJ,Mach F,Smulders YM,et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice[J]. Eur Heart J,2021,42(34):3227-3337.
[24].Ridker PM ,Everett BM,Pradhan A,et al. Low-dose methotrexate for the prevention of atherosclerotic events[J]. N Engl J Med,2019,380(8):752-762.
[25].Sabatine MS,Giugliano RP,Keech AC,et al. Evolocumab and clinical outcomes in patients with cardiovascular disease[J]. N Engl J Med,2017,376(18):1713-1722.
[26].雷浩浩,陈运清.PCSK9抑制剂对动脉粥样硬化斑块影响的研究进展[J]. 现代医药卫生,2023,39(16):2817-2821.
[27].Ji E,Lee S. Antibody-based therapeutics for atherosclerosis and cardiovascular diseases[J]. Int J Mol Sci,2021,22(11):5770.
[28].Ridker PM,Rane M. Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease[J]. Circ Res,2021,128(11):1728-1746.
[29].Ait-Oufella H,Libby P,Tedgui A. Anticytokine immune therapy and atherothrombotic cardiovascular risk[J]. Arterioscler Thromb Vasc Biol,2019,39(8):1510-1519.
[30].Lechner K,von Schacky C,McKenzie AL,et al. Lifestyle factors and high-risk atherosclerosis:pathways and mechanisms beyond traditional risk factors[J]. Eur J Prev Cardiol,2020,27(4):394-406.
[31].王宏宇.推广血管健康理念,促进血管医学专业发展[J]. 中国循环杂志,2018,33(10):1026-1028.
[32].蒋姗彤,王宏宇. 基于北京血管健康分级指导的智能化全生命周期心脏和血管健康管理[J]. 中华临床医师杂志(电子版),2019,13(11):868-871.

相似文献/References:

[1]李乐亮,综述,李萍,等.炎症标志物与颈动脉粥样斑块的稳定性[J].心血管病学进展,2016,(3):219.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.001]
　LI Leliang,LI Ping.Stability of Inflammatory Markers and Carotid Artery Plaque[J].Advances in Cardiovascular Diseases,2016,(10):219.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.001]
[2]耿春晖 关秀茹.MicroRNA作为动脉粥样硬化的诊断生物标志物的研究进展[J].心血管病学进展,2019,(7):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
　GENG Chunhui,GUAN Xiuru.microRNA as a Diagnostic Biomarker for Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(10):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
[3]乐健 何胜虎.前蛋白转化酶枯草溶菌素9致动脉粥样硬化的机制研究进展[J].心血管病学进展,2019,(7):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
　YUE Jian,HE Shenghu.Advances in the mechanism of PCSK9-induced atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(10):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
[4]武亚琳,梁斌,杨志明.NLRP3/IL-1β途径的促动脉粥样硬化作用及临床应用[J].心血管病学进展,2019,(6):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
　WU Yalin,LIANG Bin,YANG Zhiming.The Role of NLRP3/IL-1in Atherosclerosis and Clinical Application[J].Advances in Cardiovascular Diseases,2019,(10):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
[5]李琦玉 ?张宁 陈婧 黄浙勇.动脉粥样硬化的抗血小板分子靶向治疗[J].心血管病学进展,2019,(5):701.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.010]
　LI Qiyu,ZHANG Ning,CHEN Jing,et al.Anti-Platelet Molecular Targeted Therapy or Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(10):701.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.010]
[6]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
　HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(10):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[7]焦新峰 刘正霞 鲁翔.白介素-8在冠心病中的研究进展[J].心血管病学进展,2019,(8):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
　JIAO Xinfeng,LIU Zhengxia,LU Xiang.Research Progress of Interleukin-8 in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(10):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
[8]徐侨 刘正霞 鲁翔.白介素22在动脉粥样硬化和2型糖尿病中的作用[J].心血管病学进展,2019,(9):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
　XU Qiao,LIU Zhengxia,LU Xiang.IL-22 in Atherosclerosis and Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(10):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
[9]石文坚 花蕾 孟祥光 袁义强.环状RNA在冠状动脉粥样硬化性心脏病中的研究进展[J].心血管病学进展,2019,(9):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
　SHI Wenjian,HUA Lei,MENG Xiangguang,et al.CircRNA in Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2019,(10):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
[10]代承忠 彭礼清 余建群 刘静 蒲华霞.双源CT血管成像评价经导管主动脉瓣置入术术前患者颈动脉斑块[J].心血管病学进展,2019,(8):1182.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.028]
　DAI Chengzhong,PENG Liqing,YU Jianqun,et al.Evaluation of Carotid Arteries Plaques in Patients Referred for TAVI with Dual-source CT Angiography[J].Advances in Cardiovascular Diseases,2019,(10):1182.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.028]

更新日期/Last Update: 2024-11-01